

Table S1. Assignments of plasma metabolites

| Number | Metabolites | Assignment | δ ^1H (ppm) and multiplicity* |
|--------|-----------------------------|---|---|
| 1 | Lipids(mainly VLDL) | CH_3 , $(\text{CH}_2)_n$ | 0.88(t), 1.29(m) |
| 2 | Isoleucine | δCH_3 , βCH_3 , | 0.94(t), 1.01(d) |
| 3 | Proline | γCH_2 | 1.99(m) |
| 4 | Leucine | δCH_3 , βCH_3 | 0.95(d), 0.96(d) |
| 5 | Valine | γCH_3 , γCH_3 , αCH | 0.99(d), 1.03(d), 3.60(d) |
| 6 | Lactate | βCH_3 , αCH | 1.32(d), 4.11(q) |
| 7 | Alanine | βCH_3 , αCH | 1.47(d), 3.78(q) |
| 8 | Acetic Acid | γCH_3 | 1.91(s) |
| 9 | N-acetyl glycoprotein (NAG) | CH_3 | 2.03(s) |
| 10 | Glutamic Acid | βCH_2 , γCH_2 | 2.10(m), 2.34(m) |
| 11 | Glutamine | βCH_2 , γCH_2 | 2.12(m), 2.43(m) |
| 12 | Propanone | CH_3 | 2.22(s) |
| 13 | Acetoacetic Acid | CH_3 | 2.27(s) |
| 14 | Pyranic Acid | CH_3 | 2.37(s) |
| 15 | Succinic Acid | CH_2 | 2.41(s) |
| 16 | Citrate | $\text{CH}_2(1/2)$, $\text{CH}_2(1/2)$ | 2.53(d), 2.69(d) |
| 17 | Trimethylamine | CH_3 | 2.86(s) |
| 18 | Lysine | βCH | 3.03(m) |
| 19 | Choline | $\text{N}(\text{CH}_3)_3$, $\text{N}-\text{CH}_2$ | 3.20(s), 3.66(m) |
| 20 | Carnitine | $\text{CH}_2(\text{COO})$ | 3.21(s) |
| 21 | Phosphorylcholine | $\text{N}(\text{CH}_3)_3$ | 3.22(s) |
| 22 | Trimethylamine oxide (TMAO) | $\text{N}-(\text{CH}_3)_3$ | 3.26(s) |
| 23 | Scyllitol | CH | 3.35(s) |
| 24 | β -Glucose | $\text{C}-\text{H}_2$, H_3/H_5 , | 3.24(dd), 3.46(m), 3.76(dd), |
| | | $\text{CH}_2-\text{C}_6(1/2)$, | 3.90(dd), 4.64(d) |
| | | $\text{CH}_2-\text{C}_6(1/2)$, CH | |
| 25 | α -Glucose | H_4 , H_2 , $\text{H}_3, 5-\text{CH}$, | 3.41(m), 3.53(dd), 3.71(m), |
| | | $1/2$ $6-\text{CH}_2$, $1-\text{CH}$ | 3.83(m), 3.85(m), 5.23(d) |
| 26 | Glycine | CH_2 | 3.56(s) |

| Number | Metabolites | Assignment | δ ^1H (ppm) and multiplicity* |
|--------|-----------------------------|--|---|
| 27 | Threonine | αCH | 3.57(d) |
| 28 | Inositol | 4,6-CH | 3.63(s) |
| 29 | Glycerophosphocholine (GPC) | N-(CH ₃) ₃ , NCH ₂ , P-CH ₂ | 3.61(t), 3.91(m), 4.32(t) |
| 30 | 1-Methylhistidine | αCH , $\beta\text{CH}_2(1/2)$, | 3.96(dd), 3.07(d), 3.13(d) |
| | | $\beta\text{CH}_2(1/2)$ | |
| 31 | | N-CH ₃ , CH ₂ | 3.03(s), 3.93(s) |
| 32 | Triglyceride | (CH ₂) _n | 4.05(m) |
| 33 | Unsaturated Lipid | CH=CH | 5.29(m) |
| 34 | Tyrosine | H2/H6, H3/H5, | 7.18(m), 6.88(d), 3.14(m), |
| | | $\beta\text{CH}_2(1/2)$, $\beta\text{CH}_2(1/2)$ | 3.05(m) |
| 35 | Histidine. | 2-CH, 4-CH | 7.02(s), 7.72(s) |

* s: single; d: doublet; t: triplet; q: quartet; m: multiplet; dd: doublet of doublet




Figure S1. Multivariate analyses of ALL participants. Green circle: LRC, blue circle: LRN, red circle: LRC, and yellow square: NLRE. (A) Scores plot of the PCA model. (B) Score plot of the PLS-DA model. (C) The permutation test result for the PLS-DA model ($R^2 = (0.0, 0.113)$, $Q^2 = (0.0, -0.248)$).




Figure S2. Multivariate analyses of LRC and NLRE. Green circle: LRC and yellow square: NLRE. (A) Scores plot of the PCA model. (B) Score plot of the PLS-DA model. (C) The permutation test result for the PLS-DA model ($R^2 = (0.0, 0.207)$, $Q^2 = (0.0, -0.382)$).




Figure S3. Multivariate analyses of LRN and NLRE. Blue circle: LRN and yellow square:NLRE. (A) Scores plot of the PCA model. (B) Score plot of the PLS-DA model. (C) The permutation test result for the PLS-DA model ($R^2 = (0.0, 0.0537)$, $Q^2 = (0.0, -0.238)$).




Figure S4. Multivariate analyses of LRN and NLRE. Blue circle: LRN and yellow square:NLRE. (A) Scores plot of the PCA model. (B) Score plot of the PLS-DA model. (C) The permutation test result for the PLS-DA model ($R^2 = (0.0, 0.188)$, $Q^2 = (0.0, -0.359)$).

| Metabolite Set | Total | Hits | Expect | P value | Holm P | FDR | Details |
|---|-------|------|--------|---------|--------|-------|----------------------|
| Glycolysis / Gluconeogenesis | 26 | 3 | 0.222 | 0.00113 | 0.095 | 0.095 | View |
| Aminoacyl-tRNA biosynthesis | 48 | 3 | 0.41 | 0.00674 | 0.56 | 0.283 | View |
| Alanine, aspartate and glutamate metabolism | 28 | 2 | 0.239 | 0.0225 | 1.0 | 0.629 | View |
| Phenylalanine, tyrosine and tryptophan biosynthesis | 4 | 1 | 0.0342 | 0.0338 | 1.0 | 0.709 | View |
| Valine, leucine and isoleucine biosynthesis | 8 | 1 | 0.0683 | 0.0665 | 1.0 | 0.989 | View |
| Ubiquinone and other terpenoid-quinone biosynthesis | 9 | 1 | 0.0769 | 0.0745 | 1.0 | 0.989 | View |
| Phenylalanine metabolism | 10 | 1 | 0.0854 | 0.0824 | 1.0 | 0.989 | View |
| Glycerolipid metabolism | 16 | 1 | 0.137 | 0.129 | 1.0 | 1.0 | View |
| Pantothenate and CoA biosynthesis | 19 | 1 | 0.162 | 0.151 | 1.0 | 1.0 | View |
| Citrate cycle (TCA cycle) | 20 | 1 | 0.171 | 0.159 | 1.0 | 1.0 | View |
| Fructose and mannose metabolism | 20 | 1 | 0.171 | 0.159 | 1.0 | 1.0 | View |
| Selenocompound metabolism | 20 | 1 | 0.171 | 0.159 | 1.0 | 1.0 | View |
| Pyruvate metabolism | 22 | 1 | 0.188 | 0.173 | 1.0 | 1.0 | View |
| Lysine degradation | 25 | 1 | 0.214 | 0.194 | 1.0 | 1.0 | View |
| Galactose metabolism | 27 | 1 | 0.231 | 0.208 | 1.0 | 1.0 | View |
| Glyoxylate and dicarboxylate metabolism | 32 | 1 | 0.273 | 0.242 | 1.0 | 1.0 | View |
| Glycine, serine and threonine metabolism | 33 | 1 | 0.282 | 0.249 | 1.0 | 1.0 | View |
| Glycerophospholipid metabolism | 36 | 1 | 0.307 | 0.268 | 1.0 | 1.0 | View |
| Amino sugar and nucleotide sugar metabolism | 37 | 1 | 0.316 | 0.275 | 1.0 | 1.0 | View |
| Fatty acid degradation | 39 | 1 | 0.333 | 0.287 | 1.0 | 1.0 | View |
| Valine, leucine and isoleucine degradation | 40 | 1 | 0.342 | 0.294 | 1.0 | 1.0 | View |
| N-Glycan biosynthesis | 41 | 1 | 0.35 | 0.3 | 1.0 | 1.0 | View |
| Tyrosine metabolism | 42 | 1 | 0.359 | 0.306 | 1.0 | 1.0 | View |

Figure S5. Metabolic Pathway enrichment of deregulated metabolites involved in
LRC, LRN, LRE and NLRE

Table S2. Detailed information of all participants

| Number | Gender | Age(years) | BMI (kg/m ²) |
|--------|--------|------------|--------------------------|
| NLRE1 | female | 60 | 21.48 |
| NLRE2 | male | 61 | 24.84 |
| NLRE3 | female | 61 | 22.48 |
| NLRE4 | male | 63 | 25.39 |
| NLRE5 | female | 63 | 22.43 |
| NLRE6 | male | 64 | 25.74 |
| NLRE7 | male | 65 | 21.78 |
| NLRE8 | female | 66 | 24.65 |
| NLRE9 | male | 66 | 21.09 |
| NLRE10 | female | 69 | 25.97 |
| NLRE11 | female | 70 | 20.73 |
| NLRE12 | female | 70 | 20.07 |
| NLRE13 | male | 70 | 25.77 |
| NLRE14 | male | 71 | 25.62 |
| NLRE15 | female | 71 | 25.15 |
| NLRE16 | male | 72 | 18.24 |
| NLRE17 | male | 72 | 22.96 |
| NLRE18 | female | 73 | 26.27 |
| NLRE19 | female | 74 | 19.91 |
| NLRE20 | male | 75 | 22.10 |
| NLRE21 | male | 78 | 24.01 |
| NLRE22 | male | 81 | 18.63 |
| NLRE23 | male | 81 | 33.18 |
| NLRE24 | female | 82 | 26.27 |
| NLRE25 | female | 83 | 21.55 |
| NLRE26 | female | 83 | 23.73 |
| NLRE27 | female | 86 | 17.15 |
| LRE1 | male | 60 | 18.59 |
| LRE2 | male | 61 | 18.36 |
| LRE3 | male | 62 | 24.74 |
| LRE4 | male | 62 | 27.18 |
| LRE5 | male | 63 | 17.27 |
| LRE6 | male | 63 | 23.34 |
| LRE7 | female | 64 | 22.43 |
| LRE8 | female | 64 | 22.03 |
| LRE9 | female | 65 | 18.67 |
| LRE10 | male | 65 | 23.69 |
| LRE11 | male | 66 | 23.20 |
| LRE12 | male | 66 | 24.01 |
| LRE13 | female | 67 | 18.11 |

| Number | Gender | Age(years) | BMI (kg/m ²) |
|--------|--------|------------|--------------------------|
| LRE14 | male | 68 | 20.32 |
| LRE15 | male | 68 | 25.06 |
| LRE16 | male | 69 | 27.04 |
| LRE17 | male | 70 | 27.48 |
| LRE18 | male | 71 | 24.58 |
| LRE19 | male | 73 | 29.04 |
| LRE20 | male | 75 | 29.00 |
| LRE21 | female | 77 | 19.73 |
| LRE22 | female | 79 | 24.12 |
| LRE23 | female | 82 | 21.21 |
| LRE24 | female | 84 | 15.36 |
| LRE25 | female | 87 | 19.81 |
| LRE26 | male | 89 | 16.17 |
| LRN1 | female | 90 | 12.42 |
| LRN2 | male | 91 | 20.08 |
| LRN3 | female | 91 | 18.11 |
| LRN4 | female | 91 | 22.58 |
| LRN5 | female | 91 | 19.56 |
| LRN6 | female | 91 | 19.17 |
| LRN7 | female | 91 | 27.77 |
| LRN8 | female | 91 | 21.39 |
| LRN9 | female | 91 | 14.97 |
| LRN10 | male | 91 | 18.09 |
| LRN11 | male | 91 | 20.02 |
| LRN12 | female | 92 | 14.74 |
| LRN13 | female | 92 | 20.48 |
| LRN14 | female | 92 | 19.50 |
| LRN15 | female | 92 | 14.60 |
| LRN16 | female | 92 | 18.69 |
| LRN17 | female | 92 | 19.44 |
| LRN18 | female | 92 | 20.41 |
| LRN19 | female | 92 | 20.10 |
| LRN20 | male | 92 | 15.12 |
| LRN21 | female | 93 | 18.07 |
| LRN22 | female | 93 | 19.82 |
| LRN23 | female | 93 | 17.33 |
| LRN24 | female | 93 | 17.22 |
| LRN25 | male | 93 | 17.64 |
| LRN26 | male | 94 | 20.60 |
| LRN27 | male | 94 | 28.84 |
| LRN28 | male | 94 | 21.99 |
| LRN29 | female | 95 | 18.38 |

| Number | Gender | Age(years) | BMI (kg/m ²) |
|--------|--------|------------|--------------------------|
| LRN30 | female | 95 | 19.70 |
| LRN31 | female | 95 | 22.74 |
| LRN32 | female | 95 | 14.91 |
| LRN33 | female | 96 | 19.94 |
| LRN34 | female | 96 | 14.96 |
| LRN35 | female | 98 | 17.58 |
| LRN36 | female | 98 | 18.92 |
| LRN37 | female | 98 | 17.36 |
| LRC1 | male | 100 | 12.42 |
| LRC2 | female | 100 | 20.08 |
| LRC3 | female | 100 | 18.11 |
| LRC4 | male | 100 | 22.58 |
| LRC5 | female | 100 | 19.56 |
| LRC6 | female | 101 | 19.17 |
| LRC7 | female | 101 | 27.77 |
| LRC8 | female | 101 | 21.39 |
| LRC9 | male | 101 | 14.97 |
| LRC10 | female | 101 | 18.09 |
| LRC11 | female | 101 | 20.02 |
| LRC12 | female | 102 | 14.74 |
| LRC13 | female | 102 | 20.48 |
| LRC14 | female | 102 | 19.50 |
| LRC15 | female | 102 | 14.60 |
| LRC16 | female | 102 | 18.69 |
| LRC17 | female | 102 | 19.44 |
| LRC18 | female | 102 | 20.41 |
| LRC19 | female | 104 | 20.10 |
| LRC20 | female | 104 | 15.12 |
| LRC21 | female | 106 | 18.07 |
| LRC22 | female | 106 | 19.82 |
| LRC23 | female | 107 | 17.33 |
| LRC24 | female | 108 | 17.22 |
| LRC25 | female | 108 | 17.64 |
| LRC26 | female | 111 | 20.60 |
| LRC27 | female | 118 | 28.84 |
